23 Jul, 2026
According to Straits Research, the global oligonucleotide CDMO market size was valued at $1,042.20 million in 2025 and is projected to grow from $1,193.32 million in 2026 to $3,614.46 million by 2034, registering a CAGR of 14.86% during the forecast period 2026–2034.
The oligonucleotide CDMO market is driven by the expanding clinical and commercial pipeline of RNA-based therapeutics that require complex synthesis, purification, and regulatory-compliant manufacturing capabilities. Pharmaceutical and biotechnology companies increasingly rely on external CDMO partners to manage chemically modified backbones, conjugation chemistries, and stringent quality control requirements associated with antisense oligonucleotides and small interfering RNA programs. This outsourcing trend supports efficient progression from early development to commercial scale production while allowing sponsors to focus internal resources on discovery and clinical strategy. However, the market faces a restraint in the form of high technical complexity and capacity constraints associated with large-scale oligonucleotide manufacturing. Limited availability of specialized equipment, skilled personnel, and validated analytical methods creates challenges in meeting growing demand, particularly for late-stage and commercial supply. Extended lead times for facility expansion and process validation further restrict rapid scalability for CDMO providers. Despite this, the market presents a strong opportunity through rising demand for integrated end-to-end service models that combine process development, clinical manufacturing, and commercial supply within a single partnership. Sponsors increasingly prefer long-term CDMO relationships that support lifecycle management, regulatory documentation, and post-approval manufacturing continuity. Expansion of oligonucleotide applications beyond rare diseases into cardiometabolic, oncology, and inflammatory indications further broadens the addressable market for CDMO services. Additionally, growing interest in diversified supply chains and geographic manufacturing redundancy supports investment in new facilities and regional expansion, positioning the oligonucleotide CDMO market for sustained growth through comprehensive service offerings aligned with evolving therapeutic pipelines.
sales@straitsresearch.com